Author:

The monetary value of a reduction in mortality risk is often quantified using one of three concepts: the “value per statistical life” (VSL),“value per statistical life year” (VSLY),

Edward Henry, doctoral student at the University of Galway, presented a set of new recommendations for incorporating “health spillover” into the economic evaluations

The Society for Benefit-Cost Analysis 2023 annual conference featured work conducted by several CHDS researchers. Faculty member James Hammitt presented his work

People living with type 2 diabetes have a higher risk of coronary heart disease (CHD). In a CHDS seminar, Bart Ferket discussed using risk stratification to prevent CHD among diabetics.

Jacob Jameson, first-year student in the Harvard PhD Program in Health Policy, has received the 2022 Howard Raiffa Fund award. The Howard Raiffa Fund was established in 1996

Jennifer Yeh, CHDS affiliate and scientific researcher at Boston Children’s Hospital, has been promoted to Associate Professor of Pediatrics at the Harvard Medical School.

CHDS welcomes Jenna Rogers and Jacob Jameson, new students in the PhD Program in Health Policy decision science track, beginning Fall 2022. Jenna Rogers graduated from

The social value of decreasing health risks to people of different age, health status, and income depends on the evaluation framework employed in an analysis. These values can be evaluated using cost-effectiveness

Fangli Geng, Ph.D. candidate at CHDS, collaborated with researchers from the Chinese Academy of Medical Sciences & Peking Union Medical College to develop

COVID-19 vaccination is substantially more cost-effective than lockdowns, according to research conducted by CHDS faculty affiliate Joseph Pliskin and Ronen Arbel. Early in the COVID-19